Lara S. Van Der Schoot

Nijmegen, GE, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial.

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio study): An International, Pragmatic, Multicentre, Randomised, Controlled, Non-Inferiority Trial.

Journal: The Lancet regional health. Europe
Published: January 29, 2026

International consensus on dose reduction of biologics for patients with psoriasis: The DR. Delphi study.

International consensus on dose reduction of biologics for patients with psoriasis: The DR. Delphi study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: September 05, 2025

Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review.

Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review.

Journal: Frontiers in pharmacology
Published: October 03, 2024

Dose reduction of biologics in patients with plaque psoriasis: a review.

Dose reduction of biologics in patients with plaque psoriasis: a review.

Journal: Frontiers in pharmacology
Published: January 13, 2024

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice.

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice.

Journal: The Journal of dermatological treatment
Published: March 03, 2023

National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure.

National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure.

Journal: The Journal of dermatological treatment
Published: December 06, 2022

Patients' perspectives towards biologic dose reduction in psoriasis: a qualitative study.

Patients' perspectives towards biologic dose reduction in psoriasis: a qualitative study.

Journal: Archives of dermatological research
Published: November 22, 2022

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab.

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab.

Journal: The British journal of dermatology
Published: June 16, 2022

Data-driven prediction of biologic treatment responses in psoriasis: steps towards precision medicine.

Data-driven prediction of biologic treatment responses in psoriasis: steps towards precision medicine.

Journal: The British journal of dermatology
Published: June 01, 2021

Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice.

Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice.

Journal: Acta dermato-venereologica
Published: April 27, 2021

Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide.

Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide.

Journal: Archives of dermatological research
Published: April 06, 2021

Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.

Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.

Journal: Trials
Published: February 04, 2021
Showing 1-12 of 14

Last Updated: 09/26/2026